BioticsAI CEO Robhy Bustami opened up about the intense journey to FDA clearance and the tough realities of building AI tools for healthcare.
The Oakland-based startup, founded in 2021, won TechCrunch's Startup Battlefield in 2023 after impressing judges with its ultrasound AI prototype built for under $100,000.
The FDA Clearance Milestone
On December 22, 2025, the FDA issued 510(k) clearance for BioticsAI's software, enabling it to analyze prenatal ultrasounds for fetal abnormalities.
The AI copilot assesses image quality, anatomical completeness, and generates automated reports, trained on hundreds of thousands of diverse scans.
Bustami emphasized integrating regulatory strategy from day one, using pre-submission meetings to align on clinical studies and avoid common pitfalls.
Navigating Fundraising and Team Strains
Despite early pre-seed funding from Techstars and Startmate, BioticsAI bootstrapped its prototype leanly amid investor skepticism over FDA uncertainties.
Long timelines tested team morale, requiring constant alignment across engineers, clinicians, and researchers to celebrate small R&D wins like partnerships.
This three-year sprint from Battlefield pitch to clearance sets a benchmark for medtech startups balancing speed and rigor.
Broader Impact on Maternal Health
In the U.S., where maternal mortality lags behind peers, BioticsAI targets ultrasound misdiagnosis rates, especially in underserved rural areas short on OB/GYNs.
By flagging 96% of anomalies accurately, the tool promises earlier interventions, reducing anxiety for expectant parents and easing clinician workloads.
Looking ahead, BioticsAI plans hospital rollouts and expansion into gynecology, signaling FDA's maturing stance on AI diagnostics amid rising approvals.
Ultimately, such innovations democratize high-quality prenatal care, potentially averting tragedies in a field ripe for AI disruption.
Maria Lourdes
